Regular ArticleA Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced or Recurrent Adenocarcinoma of the Endometrium☆,☆☆
References (0)
Cited by (39)
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
2017, Gynecologic OncologyCitation Excerpt :Patients with metastatic, recurrent, or persistent cervical cancers have limited treatment choices and poor prognosis. Previous GOG trials of chemotherapy agents showed response rates of < 30% and 6 month PFS of < 25% in this patient population [19–25]. Thus, options for treatment of recurrent and metastatic disease are limited and novel therapies are warranted.
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
2014, Gynecologic OncologyCitation Excerpt :In this subgroup of patients, the response rate was 16% and the prolonged disease control rate was 28%. These results compare favorably with other trials of second line chemotherapy in EC where cytotoxic agents including topotecan [9], liposomal doxorubicin [10] and ifosfamide [29] have reproducibly failed to achieve a response rate in excess of 10%. Moreover recent experience with the mTOR inhibitors reveals that although the level of activity of these drugs is encouraging in women with advanced EC [30–34], they have demonstrated reproducible antitumor activity across histology subtypes, predominantly stable disease and an objective response rate from 0 to 25%.
Treatment options for advanced endometrial carcinoma
2010, Gynecologic OncologyCitation Excerpt :With more frequent use of cisplatin, carboplatin, doxorubicin, and paclitaxel in the adjuvant setting, women who have disease recurrence or develop metastastic disease face limited choices for additional treatment. The GOG has conducted numerous phase II trials of single-agent chemotherapy in the second-line treatment setting, but objective responses are seen in only a limited number of patients and typically last for only several months (Table 2) [34–40]. These observations underscore the unmet medical need for new and effective second-line therapies for endometrial adenocarcinoma.
Absence of MGMT promoter methylation in endometrial cancer
2009, Gynecologic OncologyCitation Excerpt :This however, seems unlikely in the ovarian tumor specimen we investigated. Previous studies evaluating alkylating agents such as ifosfamide and cyclophosphamide in the treatment of advanced stage or progressive endometrial cancer showed lackluster responses to this class of cytotoxics [21–22]. MGMT activity in endometrial cancers could explain in part the limited response to alkylating agents.
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies
2006, Critical Reviews in Oncology/Hematology
- ☆
Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.
- ☆☆
Presented at the 27th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, February 10–14, 1996.